GRPH News and Press, Graphite Bio Inc. From 10/05/21

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced an abstract related to the company’s sickle cell disease (SCD) research has bee...

Gene-editing companies are fighting for their share in a future multi-trillion dollar market. BEAM has a great management team, the best gene-editing technology, and follows a very smart platform licensing approach and is therefore positioned to dominated that market. Investing in...

Graphite Bio Inc. (NSD:GRPH) is one of today's notable stocks in decline, down 16.4% to $16.32. In the past 52 weeks, shares of Graphite Bio Inc. have traded between the current low of $15.90 and a high of $34.00 and is now at $16.32. Receive IBN Spotlights - "Bite Size" Small, Mid and...

Russell Microcap Index adds IPO on a quarterly basis in addition to the annual reconstitution. The following tickers will be added effective Sept. 20 for Q3 Weber (NYSE:WEBR); Graphite Bio (NASDAQ:GRPH); 1stdibs.Com (NASDAQ:DIBS); iSpecimen (NASDAQ:ISPC); Grove (NASDAQ:GRVI)&#x...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that members of the management team will participate in virtual fireside chats at the ...

Graphite Bio is a clinical-stage development biotech making use of CRISPR-based gene-editing therapy to develop a cure for sickle cell disease. Now, a biotechnology journal has published an adverse report on the safety of CRISPR-Cas9. As a result, the shares dipped, but have recov...

On track to enroll first patient in Phase 1/2 clinical trial of GPH101 for sickle cell disease in the second half of 2021 Expanded leadership team with hiring of CSO and three new appointments to board of directors Completed upsized initial public offering of common st...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial public offering of 14,000,000 shares o...

Brian Ach/Getty Images Entertainment Intellia Therapeutics ([[NTLA]] +7.7%) has gained more than 80.0% since the company joined Gilead Sciences ([[GILD]] +1.2%) over the weekend to unveil the first first-ever clinical data to support the safety and efficacy of in-vivo CRISPR genome editi...